Tammy Mah-Fraser

Tammy Mah-Fraser

Auto-generated profile, based on publicly available information

Tammy Mah-Fraser

Alberta Innovates

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2005 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
JJJohanna Jakobsdottir
Johanna Jakobsdottir
YCYvette P. Conley
Yvette P. Conley
DWDaniel Weeks
Daniel Weeks
TMTammy S. Mah
Tammy S. Mah
RFRobert E. Ferrell
Robert E. Ferrell
MGMichael B. Gorin
Michael B. Gorin

1 April 2002 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
FDF. Yesim Demirci
F. Yesim Demirci
BRBrian W. Rigatti
Brian W. Rigatti
GWGaiping Wen
Gaiping Wen
ARAmy L. Radak
Amy L. Radak
TMTammy S. Mah
Tammy S. Mah
MGMichael B. Gorin
Michael B. Gorin

1 April 2000 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
YCYvette P. Conley
Yvette P. Conley
DEDeniz Erturk
Deniz Erturk
AKAndrew Keverline
Andrew Keverline
TMTammy S. Mah
Tammy S. Mah
AKAnnahita Keravala
Annahita Keravala
MGMichael B. Gorin
Michael B. Gorin

1 January 2002 in Ophthalmic Genetics
Verified
Journal Article
Closed access
SSSilke Schmidt
Silke Schmidt
CKCaroline C. W. Klaver
Caroline C. W. Klaver
ASAnn M. Saunders
Ann M. Saunders
EPEric A. Postel
Eric A. Postel
MPMonica A. De La Paz
Monica A. De La Paz
MGMichael B. Gorin
Michael B. Gorin
Age-related maculopathy (ARM) is a multifactorial disorder known to have a substantial genetic component. The epsilon4 allele of the apolipoprotein E gene (APOE-4) has previously been reported to have a protective effect on ARM risk, while the APOE-2 allele may increase disease risk. This study combined four independent data sets (three US and one European) of Caucasian ARM patients and controls in order to obtain better statistical power to examine the role of APOE in ARM. APOE genotype and allele frequencies were compared for 617 ARM cases and 1260 controls, adjusting for age and sex differences between the two groups via multiple logistic regression. The protective effect of the APOE-4 allele on ARM risk was confirmed (age- and sex-adjusted odds ratio (OR) for APOE-4 carriers 0.54, 95% confidence interval (CI) 0.41-0.70, p < 0.0001). The effect of APOE-4 did not differ significantly between males and females and was observed consistently for both atrophic and neovascular ARM. Evidence for an increased risk of ARM due to the APOE-2 allele was found for men, but not for women (OR for men 1.54, 95% CI 0.97-2.45; OR for women 0.74, 95% CI 0.52-1.06, p = 0.01 for interaction of sex and APOE-2 carrier status). These data confirm that the APOE-4 allele, or an allele in linkage disequilibrium with it, reduces the risk of ARM. They also suggest that the effect of the APOE-2 allele may vary by gender, and that APOE-2 may confer an increased risk only to males.

1 November 2001 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
DWDaniel Weeks
Daniel Weeks
YCYvette P Conley
Yvette P Conley
HTHui-Ju Tsai
Hui-Ju Tsai
TMTammy S Mah
Tammy S Mah
PRPhilip J Rosenfeld
Philip J Rosenfeld
MGMichael B Gorin
Michael B Gorin

1 November 2002 in Cornea
Verified
Journal Article
Closed access
YGY. Jerold Gordon
Y. Jerold Gordon
RMRupinder K. Mann
Rupinder K. Mann
TMTammy S. Mah
Tammy S. Mah
MGMichael B. Gorin
Michael B. Gorin
To evaluate patients' self-assessment of their symptoms and cosmetic appearance after fluorescein-potentiated argon laser treatment (FPAL) for corneal inflammation associated with neovascularization. To describe the objective effects of FPAL therapy on established corneal neovascularization with secondary corneal edema and lipid keratopathy. Fifteen patients with corneal neovascularization resulting from various infectious and traumatic etiologies were enrolled in an open, nonrandomized pilot study. Treatment consisted of repeated sessions of intravenous fluorescein, a photosensitizer, combined with blue-green argon laser applications to abnormal corneal vessels. Patients completed a written survey to grade their symptoms and cosmetic appearance prior to treatment and at the end of the follow-up period. Objective changes in signs after FPAL treatment were described by two nonmasked ophthalmologists after slit-lamp examinations and review of serial corneal photographs. Clinical symptoms of blurred vision (p ≤ 0.003), photophobia (p ≤ 0.03), and cosmetic appearance (p ≤ 0.02) were found to be significantly improved by the patient's subjective assessment survey. There was a trend toward pain reduction (p ≤ 0.06) but no apparent reduction in tearing or foreign body sensation (p ≤ ns). Objective signs of corneal edema, neovascularization, and lipid keratopathy appeared to be reduced after FPAL therapy. FPAL therapy for corneal neovascularization, edema, and lipid keratopathy resulted in a significant reduction in symptoms and improved quality of life for 14 of 15 (93%) patients. A controlled clinical trial to confirm the reported improvement in signs observed in this pilot study should be considered.